HealthCap

HealthCap is a family of venture capital funds investing globally in life sciences and is one of the largest life science specialized VC's in Europe.

[HealthCap @HealthCapVC]

Dear friends of @HealthCapVC. We will suspend our Twitter. Communications will be through our website https://t.co/eNwWOcCVqt and Linked-In https://t.co/TicHNHhpPS.
Please follow us there.

[HealthCap @HealthCapVC]

Priothera - Positive mocravimod Phase 1b clinical data published in Transplantation and Cellular Therapy https://t.co/iUGa6G4lrC

[HealthCap @HealthCapVC]

Oncopeptides’ Pepaxti has been granted marketing authorization in the UK https://t.co/Od1fcAqzCm

[HealthCap @HealthCapVC]

Oncopeptides announces the market potential for Pepaxti in Europe https://t.co/bkF5YbWGdK

[HealthCap @HealthCapVC]

Vicore announces new data from the IPF AIR trial further strengthening the benefit-risk profile of C21 https://t.co/XywVE1sTuR

[HealthCap @HealthCapVC]

Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership https://t.co/yuzTm0Ww50

[HealthCap @HealthCapVC]

Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen https://t.co/jXZr5bqFmJ

[HealthCap @HealthCapVC]

BONESUPPORT’s CERAMENT®G used in first U.S. patient cases https://t.co/hyQC2IP4aN

[HealthCap @HealthCapVC]

Targovax - The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research – with updated publication info https://t.co/pFSG4dfmKk

[HealthCap @HealthCapVC]

Vicore selects new ATRAG as next Drug Candidate https://t.co/wCOs1MCJzO

[HealthCap @HealthCapVC]

Vicore’s digital therapeutic for IPF patients shows nearly 50% anxiety reduction in pilot study https://t.co/FJZTZp5o5S

[HealthCap @HealthCapVC]

InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth https://t.co/1GnRl0hGme

[HealthCap @HealthCapVC]

Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market https://t.co/POX4SVuwQn

[HealthCap @HealthCapVC]

Targovax receives approval to proceed with the ONCOS-102 phase 2 melanoma study from the US FDA https://t.co/zhxSNduYl6

[HealthCap @HealthCapVC]

Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC https://t.co/DpVnWYssgF

[HealthCap @HealthCapVC]

Vicore announces that C21 promotes vascular function in humans https://t.co/I6jgHCogZR

[HealthCap @HealthCapVC]

Sesen Bio and Carisma Therapeutics Announce Merger Agreement https://t.co/wXwME6qrkN

[HealthCap @HealthCapVC]

Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published https://t.co/RLtx3nvPeM

[HealthCap @HealthCapVC]

Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease https://t.co/2A3yuluI4P

[HealthCap @HealthCapVC]

Vicore provides an update on the ATTRACT-3 COVID-19 trial https://t.co/T135pT5Ohr